We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Oversight of Drug Pricing Inadequate to Control Costs, Says OIG
CMS Oversight of Drug Pricing Inadequate to Control Costs, Says OIG
Medicare Part B patients are having to pay more for their drugs because the Centers for Medicare & Medicaid Services (CMS) process for overseeing data on the average sales price (ASP) of medications is inadequate, the HHS Office of Inspector General (OIG) says in two reports released this week.